Available online on 15.10.2021 at <http://jddtonline.info>

Journal of Drug Delivery and Therapeutics

Open Access to Pharmaceutical and Medical Research

Copyright © 2021 The Author(s): This is an open-access article distributed under the terms of the CC BY-NC 4.0 which permits unrestricted use, distribution, and reproduction in any medium for non-commercial use provided the original author and source are credited



Open Access Full Text Article



Review Article

Nanoparticulate drug delivery systems: A revolution in design and development of drugs

Prashant Shukla*¹, Shweta Sharma², Padma Rao³

1. Banaras Hindu University, Institute of Technology, Department of Pharmaceutics, Varanasi-221005, India

2. Department of Pharmaceutics, ITS Pharmacy College, India

3. Department of Pharmaceutics, Dubai Pharmacy College, UAE

Article Info:



Article History:

Received 13 August 2021
Reviewed 30 September 2021
Accepted 06 October 2021
Published 15 October 2021

Cite this article as:

Shukla P, Sharma S, Rao P, Nanoparticulate drug delivery systems: A revolution in design and development of drugs, Journal of Drug Delivery and Therapeutics. 2021; 11(5-S):188-193

DOI: <http://dx.doi.org/10.22270/jddt.v11i5-S.5023>

Abstract

The recent developments in nanoparticle-based drug formulations have been helping to address issues around treating challenging diseases. Nanoparticles come in different sizes but usually vary between 100nm to 500nm. For the past few years there has been research going on in the area of drug delivery using particulate delivery systems. Various drug molecules have been modified for both pharmacokinetic and pharmacodynamic properties using nanoparticles as physical approach. Various polymers have been used in the formulation of nanoparticles for drug delivery research to increase therapeutic benefit, while minimizing side effects. Here, we review various aspects of nanoparticle formulation, characterization, effect of their characteristics and their applications in delivery of drug molecules and therapeutic genes.

Keywords: nanoparticles, applications in delivery, Liposomes, Dendrimers

*Address for Correspondence:

Prashant Shukla, Banaras Hindu University, Institute of Technology, Department of Pharmaceutics, Varanasi-221005, India

Introduction:

Use of nanoparticles has increased majorly for drug formulations and delivery since the last decade. Efforts are being put to monitor the efficiency of nanoparticles for targeted drug delivery applications. The average time and money spent for the development of a new chemical or biochemical entity are higher than that are needed to develop nanoparticle drug delivery systems¹. On the other hand, safety, efficiency factors are improved by incorporating medicine into nanoparticles drug delivery systems along with patient compliance². Majority of the latest therapies for cancer are based on nano particles approach which helps improve solubility and bioavailability of the drug at the site targeted. Due to increase in permeation the bioavailability also increases for nanoparticulated drugs especially for topically administered drugs, and so use of nanosuspensions for drug delivery has greatly increased in the recent years.

One of the main problems of drug discovery and development is developing drugs without any side effects to patients. Majority of the drug molecules are large organic molecules and are not soluble in water. So, a lot of effort has been put to nanosized the drug particles in an amorphous or crystalline nanosuspension for applications in passive targeting due to enhanced membrane diffusion³. Nanotechnology is a combination of manufacturing science

which is advanced and engineering where nanometer scaled material is being used. There is an advantage of more surface to volume ratio for a nanosized particles compared to bulk material. Nanoparticles also proved to have wide applications in various fields like agriculture to medicine.

Nano-sized inorganic particles of either simple or complex nature, display unique, physical and chemical properties and represent an increasingly important material in the development of novel nanodevices which can be used in numerous physical, biological, biomedical and pharmaceutical applications^{5,6,7}.

Different types of Nanoparticles:

Liposomes:

Liposomes are the first ones to be investigated as drug carriers. Liposomes are of 80 to 300 nm size. They are spherical vesicles contained of phospholipids and steroids. Liposomes are proven to have increased the solubility of drugs and also improve pharmacokinetic properties like therapeutic index of chemotherapeutic agents, rapid metabolism, lower side effects and also increased in vivo and in vitro anticancer activity⁴. For liposomes with size greater than 100 nm, as the size increases clearance rate by mononuclear phagocytic system increased. Liposomes that are multifunctional and containing specific antigens, proteins, biological substances could be used to design drugs

that act at specific tissue. For targeted drug delivery therapy, it is most promising type of drug delivery.

Encapsulation process is used to incorporate drug into liposomes. pH, composition of liposome, osmotic gradient, and environmental conditions regulate the release of drug from liposomes⁴. Lipid transfer, fusion, adsorption realize the interaction of liposomes with cells. Anticancer drugs⁴, antibiotics^{5,6}, anti-inflammatory and anti-rheumatic drugs^{7,8} are the drugs with liposomal formulations. Even with long history of investigation liposomes haven't made a significant impact yet. They are being extensively used in cosmetic products. Dior has first prepared the formulation in 1986.

Polymeric nanoparticles:

Nanoparticle structures with diameter ranging from 10 to 100 nm are polymeric nanomaterials. Synthetic polymers like poly ϵ -caprolactone, polyacrylamide, or natural polymers^{9,10,11} like Chitosan¹², gelatin¹³ are used to obtain Polymeric nanoparticles. Polymeric nanoparticles are further classified as biodegradable and nonbiodegradable. In order to lower immunological and intramolecular reactions between surface chemical groups polymeric nanoparticles are usually coated with nonionic surfactants.

Food and drug administration of US has approved biodegradable polymeric nanoparticles like PLA and PLGA. They are formulated in a way that they are able to encapsulate several low molecular weight compounds¹⁴. Polymeric nanoparticles are more useful in regard to biocompatibility and biodegradation profiles, when chronic dosing is needed in formulations. One downside of polymeric nanoparticles is that large scale manufacturing and production is an issue. By using a double emulsion solvent evaporation system using oil and water with vinyl alcohol PLGA nanoparticles are formulated as an emulsifier^{15,16}.

Solid Lipid Nanoparticles:

Solid lipid nanoparticles are first designed in 1990s and are utilized as an alternative for emulsions and liposomes. In biological systems Solid Lipid nanoparticles are more stable than liposomes because of their rigid core that consists of hydrophobic lipids which are solid at room temperature. By including high level of surfactants these aggregates are further stabilized. Solid lipid nanoparticles are less toxic as they are biodegradable. They can be designed with 3 types of hydrophobic designs, and they have pharmacokinetic parameters which can be controllable. These three designs are a drug enriched shell, a drug enriched core and a homogenous matrix. SLNPs could be used to deliver drugs by inhaling, topically and orally. Particles of SLN are made of solid lipids that are like highly purified triglycerides, complex glyceride mixtures or waxes stabilized by various surfactants¹⁷. Nanostructured lipid carriers and Lipid drug conjugates are modifications of lipid based nanoparticles that have been developed to overcome limitations of conventional SLN. By combining liquid lipids with solid lipids nanostructured lipid carriers are formed and as a result special nanostructured lipids are formed for which payload and prevented drug expulsion have increased. There are 3 types of NLCs, imperfect type, multiple type, and amorphous type NLCs.




Figure 1: Applications of nanoparticles

Dendrimer nanocarriers:

Dendrimer nanoparticles are unique polymers which has well defined structure and size. Some of the dendrimer nanocarriers are glycogen, amylopectin etc., Dendrimer can do multiple jobs like solubility enhancement, drug targeting. Dendrimers can be used using different routes of drug delivery oral, parenteral, nasal and intra ocular. Dendrimers can also behave like vectors in gene therapy. These 3D tree like branched molecules contain some good characteristics like narrow molecular weight distribution, and 3D structure tuned by dendrimer generation and dendron structure, and flexibility for tailored functional groups with high density on the periphery.

Carbon nanotubes:


Carbon nanotubes are first discovered in 1991. Multi walled nanotubes are prepared by pyrolysis of metallocene's like ferrocene, cobaltocene, and nickelocene under reducing conditions. Single-walled carbon nanotubes (SWNT) were prepared in a related approach using dilute hydrocarbon-organometallic mixtures.^{70,71} Interestingly, pyrolysis of nickelocene in the presence of benzene at 1100 °C yields primarily MWNT. In contrast, pyrolysis of nickelocene in the presence of acetylene yields primarily SWNT, presumably due to the smaller number of carbon atoms per molecule.

Silica nanoparticles: Sol-gel methods are used to prepare silica nanoparticles. Researcher¹⁸ had demonstrated an efficient co condensation process to monodisperse silica nanoparticles. Apart from this several other methods are described and proved to prepare silica nanoparticles like organic aqueous biphasic system described by Tan group¹⁹. MCM-41 is a mesoporous silica nanoparticle, which is usually synthesized using sol-gel processes with the presence of surfactant like C12-trimethylammonium bromide versus C16-trimethylammonium bromide, to control pore sizes.

Table 1: Different types of nanoparticle carriers for drug delivery, their structures and characteristics

Type of nanocarrier	Structure	Characteristics
Polymeric nanoparticles	Drugs are attached with a linker to the sides of linear polymer chain	These are water soluble, biodegradable and nontoxic. These type of nanoparticle drugs can target specific cells that has issue, leaving the normal cells out. They are capable of accumulating and being retentive in the tumor.
Dendrimers	Synthetic polymers with units that are repetitive and of regular pattern, which are radially emerging.	There type of nanoparticle drugs are useful in controlled degradation, high structural and chemical homogeneity, and are multifunctional
Liposomes	They are self-assembled structures composed of lipid bilayers	These type of nanoparticle drugs are easy to modify, and are capable of targeting potential areas, and they are biocompatible and amphiphilic.
Carbon nanotubes	Their structure is composed of benzene ring and carbon cylinders.	These types of drugs are water soluble and biodegradable through chemical modification and are multifunctional.
Viral nanoparticles	They contain self-assembled structures that are multivalent	They are capable of targeting specific tumor and are multifunctional. They are uniform and have defined geometry. They are also biologically compatible and are inert in nature.

Synthesis of nanoparticles:

**Figure 2: Nanoparticle Synthesis Methods**

- Chemical reduction:** One of the most commonly used methods to synthesize nanoparticles is chemical reduction of organic and inorganic reducing agents like sodium citrate, hydrogen, tollens reagent, sodium borohydride.
- Sol-Gel Process:** Wide different types of materials are used for the synthesis of nanoparticles in the method. Metal oxides like organic, inorganic, metal alkoxide are dissolved to form sol. Once sol is formed and dried a polymer network is formed in which solvent molecules are trapped inside the solid. This is called, gel, and it is dried by calcinations to form the final product.
- Polymerization:** In this process nanoparticles are formed by polymerizing monomers in an aqueous solution. Incorporation of drug is being done by either dissolving in the polymerization medium or after polymerizations is completed adsorption of nanoparticles is done. This nanoparticle suspension is purified to remove surfactants and stabilizers. This

technique is used for making polybutylcyanoacrylate or poly (alkyl cyanoacrylate) nanoparticles^{20,21}.

- Hydrothermal technique:** In hydrothermal synthesis technique synthesis is done by chemical reactions of substances in a heated environment. For single nano crystals formation synthesis is done by solubility of minerals in hot water under high pressure. Autoclave is used which contains steel pressure vessel and using this crystal growth is performed.
- Microemulsion:** For the synthesis of inorganic nanoparticles microemulsion is quite frequently used. Some researchers also suggested ways to synthesis nanoparticles withing the microemulsion. When the water droplets in the microemulsion collides the reactant exchange happens for microemulsion material like reactants. This reaction exchange is quite fats and precipitation reaction happens in nanodroplets, which in turn is followed by nucleation growth and coagulation of primary particles, that results in nanoparticle formulation.

Characteristics of Nanoparticles, and their effects on Drug Delivery:

Particle size: Particle size is an important factor in deciding nanoparticle characteristics. They decide toxicity, fate biologically and ability of targeting in nanoparticle systems. Along with that they could also affect drug loading, release rate of drug and stability of nanoparticles. Many research studies have proved that nanoparticles of sub micron sized have more uses than microparticles²². Intracellular uptake is more in nanoparticles than microparticles and are available to wide range of targets as they are relatively smaller in size and more mobile. It was found in the research that nanoparticles of 100nm had an uptake which is 2.5 times greater than 1 μ m microparticles. And the uptake is 6 times greater than 10 μ m microparticles²³. In another study it was proved that nanoparticles penetrated through submucosal layers in rate in situ intestinal loop model, while microparticles are local to epithelial lining²⁴. Nanoparticles that are tween 80 coated have crossed the blood brain barrier. Compared to microparticles some cell line submicron nano particles can be consumed efficiently.

Particle size will have affect on drug delivery. Particles of small size will have large surface area, and major part of the drug associated would be at or near the particle surface, which leads to fast drug release. On the other hand, particles of large size will have large cores which allow drug to be encapsulated and leads to slow diffusion of drug²⁵. During the nanoparticle dispersion, transportation and storage smaller particles have greater risk of aggregation. It is difficult to formulate nanoparticles in small size but with good stability. The most commonly used routine method used to determine particle size is photon correlation spectroscopy or dynamic scattering. Viscosity of the medium is necessary to be known in order to determine the diameter of particle.

Surface properties of nanoparticles: Nanoparticles are determined easily by immune system of body when they are administered and are cleared by phagocytes for the circulation²⁶. The amounts of proteins adsorbed are determined by size of nanoparticles and their surface hydrophobicity, and in vivo fate of nanoparticles is influenced by this²⁷. The process of binding opsonin to nanoparticles surface is called opsonization and it acts as bridge between phagocytes and nanoparticles.

In order to increase the success rate of nanoparticle-based drug targeting, it is important to lower the opsonization and to extend the nanoparticle circulation in vivo. This process can be achieved by:

- Nanoparticles surface coating using hydrophilic polymers and surfactants.
- Formulation of nanoparticles with biodegradable copolymers with PEG, poloxamer, poloxamine and polysorbate 80.

Drug Loading:

Drug loading capacity is one of the important factors of a successful nanoparticle drug delivery system. Drug loading capacity needs to be high, and that helps reduce the amount of matrix materials needed for administration. Drug loading can be achieved by two methods:

- One method is incorporation method in which drug is incorporated at the time of nanoparticle production
- Drug absorption after nanoparticles are formed by incubating the carrier with a concentrated drug solution, which is called absorption technique.

Drug loading and entrapment efficiency depend on solid state drug solubility in polymer which in turn relates to the drug polymer interactions and molecular weight.

Drug Release:

Drug release is an important factor for a successful nanoparticulate drug delivery system. Usually drug release depends on two factors

- Solubility of drug
- Desorption of the surface drug
- Diffusion of drug through nanoparticle matrix
- Combination of erosion/ diffusion process

When it comes to nanospheres drug will be uniformly distributed and the release happens by erosion of the matrix under sink conditions. If the matrix erosion is slower than drug diffusion, release mechanism is controlled by a diffusion process.

Nanoparticulate Drug delivery systems and applications:

Recently several articles have been published both research and review on nano vehicular intracellular drug delivery systems, one of them includes an article published by Prokop and Davidson²⁹. This article includes several aspects of nanodrug delivery systems and their use in biological systems at cellular levels. Various nano systems and their applications has been reviewed. Another researcher has discussed the role of nanotechnology in drug design in a detail way with several drugs and references³⁰. Nanoparticles based drug delivery systems and their treatment towards chronic pulmonary disease has been explained in³¹. With all these research studies it was proved that nanoparticulate drug delivery systems show a promising approach to achieve desired drug delivery properties by modifying pharmacokinetic properties. Authors Gupta and Moulik has given a detailed description on nano emulsions³². To overcome diseases that are cause through genes, it is good to combat the root cause rather than treating the disease, and gene therapy for it is a promising strategy³³. Researchers³⁴ have discussed need for non toxic and efficient gene delivery vectors in nano lipoplex gene delivery.

Liposomes offer good option for delivering chemotherapeutic agents. In addition to that micelles are also great to make insoluble drugs soluble as they have hydrophobic core. Several different forms of nanoparticles have shown good progress in treating cancer, and one of them was carbon nanotubes. It is carbon in allotropic form with framework in cylindrical framework. They are classified into single walled carbon nanotubes and multiwalled depending on the number of sheets in concentric cylinders. Drug can be loaded easily into carbon nanotubes as they have hollow interiors. Use of nanoparticles in diagnostic testing has been explored widely in the recent years³⁵, as the current technology that has been use for this is hindered by inadequacies of fluorescent markers like fluorescence fading after single use, dyes and restricted usage. Nanoparticles provide good use to overcome these problems. Recently theranostic nanoparticles have gained lot of attention for diagnostic reasons. The primary reasons of stokes are vascular diseases like atherosclerosis and hypertension³⁶⁻⁴¹. For the diagnosis and detection nanoparticles have been used for atherosclerotic plaques. Same kind of targeting strategies are used to deliver therapeutic agents to these plaque. Identifying the disease at early stages and intervening it may prevent the worst outcomes that may lead to plaque rupture and thrombosis.

References:

1. Bhowmik D, Duraivel S, Kumar KS. Recent trends in challenges and opportunities in transdermal drug delivery system. *The Pharma Innovation*. 2012; 1(10). [Google Scholar]
2. NirvedV U, Lokesh V, Prasad MG, Joshi HM. Formulation and evaluation of ethosomes of sesbania grandiflora linn. Seeds. *Novel Science International Journal of Pharmaceutical Science*. 2012; 1:274-5. [Google Scholar]
3. Pan BF, Gao F, Gu HC: Dendrimer modified magnetite nanoparticles for protein immobilization. *Journal of colloid and interface science*, 2005; 284(1):1-6. <https://doi.org/10.1016/j.jcis.2004.09.073>
4. dos Santos Giuberti C, de Oliveira Reis EC, Ribeiro Rocha TG, Leite EA, Lacerda RG, Ramaldes GA, de Oliveira MC: Study of the pilot production process of long-circulating and pH-sensitive liposomes containing cisplatin. *Journal of liposome research*, 2011; 21(1):60-69. <https://doi.org/10.3109/08982101003754377>

5. Salata, Oleg V. "Applications of nanoparticles in biology and medicine." *Journal of nanobiotechnology*. 2004; 2(1):1-6. <https://doi.org/10.1186/1477-3155-2-1>
6. Paull R, Wolfe J, Hebert P, Sinkula M: Investing in nanotechnology. *Nature Biotechnology*. 2003; 21(10):1144-1147. 10.1038/nbt1003-1144. <https://doi.org/10.1038/nbt1003-1144>
7. Manne R, Devarajan A. Development of nicotinic acid controlled release tablets with natural phenolic anti-oxidant polymer by encapsulation technique. *Journal of Natural Remedies*. 2021; 20(4):204-16. <https://doi.org/10.18311/jnr/2020/25514>
8. van den Hoven JM, Van Tomme SR, Metselaar JM, Nuijen B, Beijnen JH, Storm G: Liposomal drug formulations in the treatment of rheumatoid arthritis. *Molecular pharmaceuticals*, 2011; 8(4):1002-1015. <https://doi.org/10.1021/mp2000742>
9. Bilensoy E, Sarisozen C, Esendagl G, Dogan LA, Aktas Y, Sen M, Mangan AN: Intravesical cationic nanoparticles of chitosan and polycaprolactone for the delivery of Mitomycin C to bladder tumors. *International journal of pharmaceuticals*. 2009; 371(1-2):170-176 <https://doi.org/10.1016/j.ijpharm.2008.12.015>
10. Bai J, Li Y, Du J, Wang S, Zheng J, Yang O, Chen X: One-pot synthesis of polyacrylamide-gold nanocomposite. *Materials Chemistry and Physics*. 2007; 106(2-3): 412-415. <https://doi.org/10.1016/j.matchemphys.2007.06.021>
11. Turos E, Shim JY, Wang Y, Greenhalgh K, Reddy GS, Dickey S, Lim DV: Antibiotic-conjugated polyacrylate nanoparticles: New opportunities for development of anti-MRSA agents. *Bioorganic & medicinal chemistry letters*. 2007; 17(1):53-56. <https://doi.org/10.1016/j.bmcl.2006.09.098>
12. Kurakula M, Naveen N R, Patel B, Manne R, Patel DB. Preparation, Optimization and Evaluation of Chitosan-Based Avanafil Nanocomplex Utilizing Antioxidants for Enhanced Neuroprotective Effect on PC12 Cells. *Gels*. 2021; 7(3):96. <https://doi.org/10.3390/gels7030096>
13. Saraogi GK, Gupta P, Gupta UD, Jain NK, Agrawal GP. Gelatin nanocarriers as potential vectors for effective management of tuberculosis. *International journal of pharmaceuticals*. 2010; 385(1-2):143-149. <https://doi.org/10.1016/j.ijpharm.2009.10.004>
14. Panyam J, Labhasetwar V. Sustained cytoplasmic delivery of drugs with intracellular receptors using biodegradable nanoparticles. *Molecular pharmaceuticals*. 2004; 1(1):77-84. <https://doi.org/10.1021/mp034002c>
15. Prabha S, Labhasetwar V. Critical determinants in PLGA/PLA nanoparticle-mediated gene expression. *Pharmaceutical research*. 2004; 21(2):354-364. <https://doi.org/10.1023/B:PHAM.0000016250.56402.99>
16. Murakami, H., Kobayashi, M., Takeuchi, H., & Kawashima, Y. Preparation of poly (DL-lactide-co-glycolide) nanoparticles by modified spontaneous emulsification solvent diffusion method. *International journal of pharmaceuticals*. 1999; 187(2):143-152. [https://doi.org/10.1016/S0378-5173\(99\)00187-8](https://doi.org/10.1016/S0378-5173(99)00187-8)
17. Kovacevic A, Savic S, Vuleta G, Mueller RH, Keck CM. Polyhydroxy surfactants for the formulation of lipid nanoparticles (SLN and NLC): effects on size, physical stability and particle matrix structure. *International journal of pharmaceuticals*. 2011; 406(1-2):163-72. <https://doi.org/10.1016/j.ijpharm.2010.12.036>
18. Stöber W, Fink A, Bohn E. Controlled growth of monodisperse silica spheres in the micron size range. *Journal of colloid and interface science*. 1968; 26(1):62-9. [https://doi.org/10.1016/0021-9797\(68\)90272-5](https://doi.org/10.1016/0021-9797(68)90272-5)
19. Vallet-Regi M, Rámila A, Del Real RP, Pérez-Pariente J. A new property of MCM-41: drug delivery system. *Chemistry of Materials*. 2001; 13(2):308-11. <https://doi.org/10.1021/cm0011559>
20. Zhang Q, Shen Z, Nagai T. Prolonged hypoglycemic effect of insulin-loaded polybutylcyanoacrylate nanoparticles after pulmonary administration to normal rats. *International journal of pharmaceuticals*. 2001; 218(1-2):75-80. [https://doi.org/10.1016/S0378-5173\(01\)00614-7](https://doi.org/10.1016/S0378-5173(01)00614-7)
21. Boudad H, Legrand P, Lebas G, Cheron M, Duchene D, Ponchel G. Combined hydroxypropyl- β -cyclodextrin and poly (alkylcyanoacrylate) nanoparticles intended for oral administration of saquinavir. *International journal of pharmaceuticals*. 2001; 218(1-2):113-24. [https://doi.org/10.1016/S0378-5173\(01\)00622-6](https://doi.org/10.1016/S0378-5173(01)00622-6)
22. Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. *Advanced drug delivery reviews*. 2003; 55(3):329-47. [https://doi.org/10.1016/S0169-409X\(02\)00228-4](https://doi.org/10.1016/S0169-409X(02)00228-4)
23. Desai MP, Labhasetwar V, Walter E, Levy RJ, Amidon GL. The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent. *Pharmaceutical research*. 1997; 14(11):1568-73. <https://doi.org/10.1023/A:1012126301290>
24. Desai MP, Labhasetwar V, Amidon GL, Levy RJ. Gastrointestinal uptake of biodegradable microparticles: effect of particle size. *Pharm Res* 1996; 13:1838-45 <https://doi.org/10.1023/A:1016085108889>
25. Redhead HM, Davis SS, Illum L. Drug delivery in poly (lactide-co-glycolide) nanoparticles surface modified with poloxamer 407 and poloxamine 908: in vitro characterisation and in vivo evaluation. *Journal of Controlled Release*. 2001; 70(3):353-63. [https://doi.org/10.1016/S0168-3659\(00\)00367-9](https://doi.org/10.1016/S0168-3659(00)00367-9)
26. Swarbrick J, Boylan J. *Encyclopedia of pharmaceutical technology*. 2nd ed.; Marcel Dekker: New York, 2002. 34.
27. Müller RH, Wallis KH. Surface modification of iv injectable biodegradable nanoparticles with poloxamer polymers and poloxamine 908. *International journal of pharmaceuticals*. 1993; 89(1):25-31. [https://doi.org/10.1016/0378-5173\(93\)90304-X](https://doi.org/10.1016/0378-5173(93)90304-X)
28. Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. *Advanced drug delivery reviews*. 2012; 64:24-36. <https://doi.org/10.1016/j.addr.2012.09.006>
29. Prokop A, Davidson JM. Nanovehicular intracellular delivery systems. *Journal of pharmaceutical sciences*. 2008; 97(9):3518-90. <https://doi.org/10.1002/jps.21270>
30. Devapally H, Chakilam A, Amiji MM. Role of nanotechnology in pharmaceutical development. *J Pharm Sci*. 2007; 96:2547-65. <https://doi.org/10.1002/jps.20875>
31. Singh R, Lillard Jr JW. Nanoparticle-based targeted drug delivery. *Experimental and molecular pathology*. 2009; 86(3):215-23. <https://doi.org/10.1016/j.yexmp.2008.12.004>
32. Gupta S, Moulik SP. Biocompatible microemulsions and their prospective uses in drug delivery. *Journal of pharmaceutical sciences*. 2008; 97(1):22-45. <https://doi.org/10.1002/jps.21177>
33. Murakami H, Kobayashi M, Takeuchi H, Kawashima Y. Utilization of poly (DL-lactide-co-glycolide) nanoparticles for preparation of mini-depot tablets by direct compression. *Journal of Controlled Release*. 2000; 67(1):29-36. [https://doi.org/10.1016/S0168-3659\(99\)00288-6](https://doi.org/10.1016/S0168-3659(99)00288-6)
34. Mozafari MR, Omri A. Importance of divalent cations in nanolipoplex gene delivery. *Journal of pharmaceutical sciences*. 2007; 96(8):1955-66. <https://doi.org/10.1002/jps.20902>
35. Kolluru LP, Rizvi SA, D'Souza M, D'Souza MJ. Formulation development of albumin based theragnostic nanoparticles as a potential delivery system for tumor targeting. *Journal of drug targeting*. 2013; 21(1):77-86. Google Scholar <https://doi.org/10.3109/1061186X.2012.729214>
36. Chikan V, McLaurin EJ. Rapid nanoparticle synthesis by magnetic and microwave heating. *Nanomaterials*. 2016; 6(5):85. <https://doi.org/10.3390/nano6050085>. <https://doi.org/10.3390/nano6050085>
37. Ruel-Gariépy E, Shive M, Bichara A, Berrada M, Le Garrec D, Chenite A, Leroux JC. A thermosensitive chitosan-based hydrogel for the local delivery of paclitaxel. *European Journal of*

- Pharmaceutics and Biopharmaceutics. 2004; 57(1):53-63. [PubMed] [Google Scholar] [https://doi.org/10.1016/S0939-6411\(03\)00095-X](https://doi.org/10.1016/S0939-6411(03)00095-X)
38. Ramanan RM, Chellamuthu P, Tang L, Nguyen KT. Development of a temperature-sensitive composite hydrogel for drug delivery applications. *Biotechnology progress*. 2006; 22(1):118-25. [PubMed] [Google Scholar] <https://doi.org/10.1021/bp0501367>
39. Paavola A, Kilpeläinen I, Yliruusi J, Rosenberg P. Controlled release injectable liposomal gel of ibuprofen for epidural analgesia. *International journal of pharmaceutics*. 2000; 199(1):85-93. [https://doi.org/10.1016/S0378-5173\(00\)00376-8](https://doi.org/10.1016/S0378-5173(00)00376-8)
40. Murakami H, Kobayashi M, Takeuchi H, Kawashima Y. Further application of a modified spontaneous emulsification solvent diffusion method to various types of PLGA and PLA polymers for preparation of nanoparticles. *Powder technology*. 2000; 107(1-2):137-43. [https://doi.org/10.1016/S0032-5910\(99\)00182-5](https://doi.org/10.1016/S0032-5910(99)00182-5)
41. Murakami H, Kobayashi M, Takeuchi H, Kawashima Y. Evaluation of poly (DL-lactide-co-glycolide) nanoparticles as matrix material for direct compression. *Advanced Powder Technology*. 2000; 11(3):311-22. <https://doi.org/10.1163/156855200750172187>